mRNA-based vaccines, which have never before been approved by the FDA, may have their breakout moment with Covid-19.
Clinical studies and scientific research suggest that mRNA therapies could alter the R&D landscape of the biopharmaceutical industry.
Moderna, a leader in mRNA therapeutics, is a frontrunner in the race to develop a Covid-19 vaccine.
We view FDA approval of MRNA’s Covid-19 vaccine as likely in 2021 and we anticipate that positive data catalysts will drive share upside in the near term
Please visit our website for more examples of CFRA's fundamental research.